Parkinson's disease is associated with increased serum levels of macrophage migration inhibitory factor

Cytokine

Volumn 55, Issue 2, 2011, Pages 165-167

  Nicoletti, Alessandra ^a   Fagone, Paolo ^a   Donzuso, Giulia ^a   Mangano, Katia ^a   Dibilio, Valeria ^a   Caponnetto, Salvatore ^a   Bendtzen, Klaus ^b   Zappia, Mario ^b   Nicoletti, Ferdinando ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MACROPHAGE MIGRATION INHIBITION FACTOR; MONOAMINE OXIDASE INHIBITOR;

ADULT; BLOOD ANALYSIS; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE SEQUENCE; HUMAN; LETTER; MALE; ONSET AGE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; UNIFIED PARKINSON DISEASE RATING SCALE;

ADOLESCENT; ADULT; AGED; EPILEPSY; FEMALE; HUMANS; INFLAMMATION; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MIDDLE AGED; PARKINSON DISEASE; YOUNG ADULT;

EID: 79959534690     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2011.03.027     Document Type: Letter

References (14)

1. Obeso J.A., Rodriguez-Oroz M.C., Goetz C.G., Marin C., Kordower J.H., Rodriguez M., et al. Missing pieces in the Parkinson's disease puzzle. Nat Med 2010, 16:653-661.
2. Hirsch E.C., Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurol 2009, 8:382-397.
3. Stypula G., Kunert-Radek J., Stepien H., Zylinska K., Pawlikowski M. Evaluation of interleukins ACTH, cortisol and prolactin concentrations in the blood of patients with parkinson's disease. Neuroimmunomodulation 1996, 3:131-134.
4. Dobbs R.J., Charlett A., Purkiss A.G., Dobbs S.M., Weller C., Peterson D.W. Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism. Acta neurologica Scandinavica 1999, 100:34-41.
5. Reale M., Iarlori C., Thomas A., Gambi D., Perfetti B., Di Nicola M., et al. Peripheral cytokines profile in Parkinson's disease. Brain Behav Immun 2009, 23:55-63.
6. Stosic-Grujicic S., Stojanovic I., Nicoletti F. MIF in autoimmunity and novel therapeutic approaches. Autoimmun Rev 2009, 8:244-249.
7. Hughes A.J., Ben-Shlomo Y., Daniel S.E., Lees A.J. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 1992, 42:1142-1146.
8. ILAE, Guidelines for epidemiologic studies on epilepsy. Commission on Epidemiology and Prognosis, International League Against Epilepsy. Epilepsia (1993) 34: 592-596.
9. Loots G.G., Chain P.S., Mabery S., Rasley A., Garcia E., Ovcharenko I. Array2BIO: from microarray expression data to functional annotation of co-regulated genes. Array2BIO: from microarray expression data to functional annotation of co-regulated genes. BMC Bioinformatics 2006, 7:307-308.
10. Colantuoni C., Henry G., Zeger S., Pevsner J. Local mean normalization of microarray element signal intensities across an array surface. quality control and correction of spatially systematic artifacts. Biotechniques 2002, 32:1316-1320.
11. Hoehn M.M., Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology 1967, 17:427-442.
12. Fahn S. Drug treatment of hyperkinetic movement disorders. Semin Neurol 1987, 7(2):192-208. Semin Neurol (1987) 7(2):192-208.
13. Matsunaga J., Sinha D., Solano F., Santis C., Wistow G., Hearing V. Macrophage migration inhibitory factor (MIF) - its role in catecholamine metabolism. Cell Mol Biol 1999, 45:1035-1040.
14. Schwarz S.C., Schwarz J., Sautter J., Oertel W.H. Effects of macrophage migration inhibitory factor and macrophage migration stimulatory factor on function and survival of foetal dopaminergic grafts in the 6-hydroxydopamine rat model of Parkinson's disease. Exp Brain Res 1998, 120:95-103.